|
ag凯发旗舰厅
 shanghai clinical research center (scrc) operates as a 3rd-party full-service assessment and resource center to facilitate drug development. scrc is developing a core resource platform with coverage of clinical research sites throughout china. a fully equipped central laboratory with glp capabilities, a state-of-the-art data management and a bio-statistics system position scrc as a leader in drug development services in china. founded under the collaborative framework of the ministry of science and technology and the shanghai municipality in 2008, scrc endeavors to be a pioneer in the globalization of drug development in china by provision of the link necessary between pharmaceutical companies and hospitals.
bbmri (biobanking and biomolecular resources research infrastructure) was one of the first european research infrastructure projects funded by the european commission (ec). the ec-funded preparatory phase of bbmri came to its end in january 2011. during the past 3 years bbmri has grown into a 53-member consortium with over 280 associated organisations (largely biobanks) from over 30 countries, making it the largest research infrastructure project in europe. during the preparatory phase the concept of a functional pan-european biobank was formulated and has now been presented to member states of the european union and for associated states for approval and funding.
the mission
to benefit european health-care, medical research, and, ultimately, the health of the citizens of the european union; to have a sustainable legal and financial conceptual framework for a pan-european biobank infrastructure; to increase scientific excellence and efficacy of european research in the life sciences, especially in biomedical research; to expand and secure competitiveness of european research and industry in a global context, especially in the field of medicine and biology.
participating members
scientific partners: 30
funding organisations (ministries, research councils): 24
associated partners: >150
founded in 1964, the french national institute of health and medical research (inserm) is a public scientific and technological institute which operates under the joint authority of the french ministry of health and french ministry of research.
as the only french public research institute to focus entirely on human health, in 2008 inserm took on the responsibility for the strategic, scientific and operational coordination of biomedical research. this key role as coordinator comes naturally to inserm thanks to the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient's bed.
the decree adopted in march 2009 will enable inserm to perform its research missions in the face of the new scientific, health and economic challenges of the 21st century. scientific monitoring and expertise are now part of the institute's official missions.
from the outset, institute has forged close partnerships with the other public and private research establishments as well as hospitals to fulfil its missions. 80% of inserm's 318 research units are currently set up in university hospitals or cancer research centers. the research campuses of the french national center for scientific research (cnrs), along with the pasteur and curie institutes, also house inserm research divisions. with the law on the independence of universities placing them at the heart of the research policy, they will also be a key partner of inserm.
uk biobank has the support of leading scientists from the uk and around the world. we are funded by the wellcome trust, the uk's largest independent medical research charity, the medical research council, the department of health, the scottish government, british heart foundation and the northwest regional development agency. we also have the backing of many of the uk's major medical research charities. the project is also supported by the national health service.
the uk biobank resource aims to include 500,000 people from all around the uk who are currently aged 40-69. this age group is being studied because it involves people at risk over the next few decades of developing a wide range of important diseases (including cancer, heart disease, stroke, diabetes, dementia). the uk national health service treats the single largest group of people anywhere in the world, and keeps detailed records on all of them from birth to death. consequently, prolonged follow-up of participants through routine medical and other health-related records will allow the identification of comparatively large numbers of individuals who develop each of a wide range of disabling and life-threatening conditions. because uk biobank will involve extensive baseline questionnaire and physical measures, as well as stored blood and urine samples that allow many different types of assay (e.g. genetic, proteomic, metabonomic, biochemical and haematologic), it will be a uniquely rich resource for investigating why some people develop particular diseases while others do not. this will help researchers to understand the causes of diseases better, and to find new ways to prevent and treat many different conditions.
|
